Archetype

Archetype Therapeutics is an AI-native biotechnology company that leverages generative chemogenomics to transform drug discovery and development. The company's proprietary platform integrates deep learning with large-scale patient clinicogenomic data to virtually screen billions of drug-like molecules per day. By predicting the impact of molecules on complex biological states and clinical outcomes, Archetype identifies therapies for diseases with high unmet needs. Its current pipeline focuses on oncology and respiratory conditions, including early-stage lung adenocarcinoma and metastatic prostate cancer. Archetype is advancing both novel small molecules and antibody-drug conjugates (ADCs) through strategic partnerships with organizations like Abzena and Alloy Therapeutics. The company's approach aims to bypass the limitations of single-target discovery by focusing on broader disease biology and patient-driven data.